PhD Lenka Besse
Medizinische Onkologie und Hämatologie · Dept. I
HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024
05.07.2024HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
05.07.2024Br J Cancer 2024
Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka
A replicating LCMV-based vaccine for the treatment of solid tumors.
Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger K, Bald T, Schietinger A, Schürch C, Ring S, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Ther 2023
05.12.2023A replicating LCMV-based vaccine for the treatment of solid tumors.
05.12.2023Mol Ther 2023
Purde Mette-Triin, Cupovic Jovana, Palmowski Yannick A, Makky Ahmad, Schmidt Sarah, Rochwarger Alexander, Hartmann Fabienne, Stemeseder Felix, Lercher Alexander, Abdou Marie-Therese, Bomze David, Besse Lenka, Berner Fiamma, Tüting Thomas, Hölzel Michael, Bergthaler Andreas, Kochanek Stefan, Ludewig Burkhard, Lauterbach Henning, Orlinger Klaus K, Bald Tobias, Schietinger Andrea, Schürch Christian M, Ring Sandra Stephanie, Flatz Lukas
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo G, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol 2023; 12:71.
10.08.2023Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
10.08.2023Exp Hematol Oncol 2023; 12:71
Bandini Cecilia, Mereu Elisabetta, Paradzik Tina, Labrador Maria, Maccagno Monica, Cumerlato Michela, Oreglia Federico, Prever Lorenzo, Manicardi Veronica, Taiana Elisa, Ronchetti Domenica, D'Agostino Mattia, Gay Francesca, Larocca Alessandra, Besse Lenka, Merlo Giorgio Roberto, Hirsch Emilio, Ciarrocchi Alessia, Inghirami Giorgio Ga, Neri Antonino, Piva Roberto
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.
17.03.2023The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
17.03.2023Sci Rep 2023; 13:4411
Besse Lenka, Kraus Marianne, Besse Andrej, Driessen Christoph, Tarantino Ignazio
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson I, Patiño-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong S, Wolf J, Martin T, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey A, Mullins R, Eyquem J, Wells J, Wiita A. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun 2022; 13:4121.
15.07.2022The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
15.07.2022Nat Commun 2022; 13:4121
Ferguson Ian D, Patiño-Escobar Bonell, Tuomivaara Sami T, Lin Yu-Hsiu T, Nix Matthew A, Leung Kevin K, Kasap Corynn, Ramos Emilio, Nieves Vasquez Wilson, Talbot Alexis, Hale Martina, Naik Akul, Kishishita Audrey, Choudhry Priya, Lopez-Girona Antonia, Miao Weili, Wong Sandy W, Wolf Jeffrey L, Martin Thomas G, Shah Nina, Vandenberg Scott, Prakash Sonam, Besse Lenka, Driessen Christoph, Posey Avery D, Mullins R Dyche, Eyquem Justin, Wells James A, Wiita Arun P
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.
26.05.2022Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
26.05.2022Front Oncol 2022; 12:899272
Schwestermann Jonas, Besse Andrej, Driessen Christoph, Besse Lenka
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Bolomsky A, Caers J, Hübl W, Schreder M, Zojer N, Driessen C, Tang J, Besse L, Heckman C, Kubicek S, Hannich J, Miettinen J, Malyutina A, Besse A, Huber J, Fellinger S, Breid H, Parsons A, Klavins K, Ludwig H. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5:4125-4139.
26.10.2021Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
26.10.2021Blood Adv 2021; 5:4125-4139
Bolomsky Arnold, Caers Jo, Hübl Wolfgang, Schreder Martin, Zojer Niklas, Driessen Christoph, Tang Jing, Besse Lenka, Heckman Caroline A, Kubicek Stefan, Hannich J Thomas, Miettinen Juho J, Malyutina Alina, Besse Andrej, Huber Julia, Fellinger Stefanie, Breid Helene, Parsons Alun, Klavins Kristaps, Ludwig Heinz
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells 2021; 10
22.10.2021High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
22.10.2021Cells 2021; 10
Besse Lenka, Besse Andrej, Kraus Marianne, Maurits Elmer, Overkleeft Herman S, Bornhauser Beat, Bourquin Jean-Pierre, Driessen Christoph
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Besse L, Pilon M, Farhan H, Vulpe C, Overkleeft H, Driessen C, Ståhlman M, Huber J, Bolomsky A, Ludwig H, Hannich J, Loguinov A, Everts B, Berkers C, Besse A, Borén J, Florea B, Sathianathan M, Stolze S, Sobh A, Zaal E, van der Ham A, Ruiz M, Phuyal S, Büchler L. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Res 2021; 81:4581-4593.
22.06.2021Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
22.06.2021Cancer Res 2021; 81:4581-4593
Besse Lenka, Pilon Marc, Farhan Hesso, Vulpe Christopher D, Overkleeft Herman S, Driessen Christoph, Ståhlman Marcus, Huber Julia, Bolomsky Arnold, Ludwig Heinz, Hannich J Thomas, Loguinov Alex, Everts Bart, Berkers Celia R, Besse Andrej, Borén Jan, Florea Bogdan I, Sathianathan Marc, Stolze Sara C, Sobh Amin, Zaal Esther A, van der Ham Alwin J, Ruiz Mario, Phuyal Santosh, Büchler Lorina
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. Hemasphere 2021; 5:e602.
12.06.2021Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
12.06.2021Hemasphere 2021; 5:e602
Byrgazov Konstantin, Besse Andrej, Kraus Marianne, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2020; 101:106499.
31.12.2020Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
31.12.2020Leuk Res 2020; 101:106499
Byrgazov Konstantin, Kraus Marianne, Besse Andrej, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
Brenig R, Antoniades C, Wendon J, Heim M, Ludewig B, Weston C, Duong F, Semela D, Brand S, Boldanova T, Künzler-Heule P, Cupovic J, Besse L, Pérez Shibayama C, Singanayagam A, Geng A, Triantafyllou E, Pop O, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2019; 3
10.12.2019Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
10.12.2019Life Sci Alliance 2019; 3
Brenig Robert, Antoniades Charalambos G, Wendon Julia, Heim Markus H, Ludewig Burkhard, Weston Christopher J, Duong François Ht, Semela David, Brand Stephan, Boldanova Tuyana, Künzler-Heule Patrizia, Cupovic Jovana, Besse Lenka, Pérez Shibayama Christian Ivan, Singanayagam Arjuna, Geng Anne, Triantafyllou Evangelos, Pop Oltin, Bernsmeier Christine
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
Vrabel D, Sevcikova S, Pour L, Stork M, Sandecka V, Jelinek T, Plonkova H, Jarkovsky J, Brožová L, Kubaczkova V, Almasi M, Bezdekova R, Rihova L, Besse L, Sedlarikova L, Hájek R. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. Eur J Haematol 2019
25.11.2019Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
25.11.2019Eur J Haematol 2019
Vrabel David, Sevcikova Sabina, Pour Ludek, Stork Martin, Sandecka Viera, Jelinek Tomas, Plonkova Hana, Jarkovsky Jiri, Brožová Lucie, Kubaczkova Veronika, Almasi Martina, Bezdekova Renata, Rihova Lucie, Besse Lenka, Sedlarikova Lenka, Hájek Roman
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
27.08.2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
27.08.2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
20.09.2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
20.09.2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.
15.03.2018The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
15.03.2018JOR Spine 2018; 1:e1003
Krupkova Olga, Cambria Elena, Besse Lenka, Besse Andrej, Bowles Robert, Wuertz-Kozak Karin
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
21.11.2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
21.11.2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
28.07.2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
28.07.2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
05.07.2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
05.07.2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.
23.06.2015The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
23.06.2015Cancer Chemother Pharmacol 2015; 76:383-96
Kraus Johannes, Kraus Marianne, Liu Nora, Besse Lenka, Bader Jürgen, Geurink Paul P, de Bruin Gerjan, Kisselev Alexei F, Overkleeft Herman, Driessen Christoph